Other studies have evaluated the feasibility of various chimeric antigen receptor (CAR)-modified T cells recognising antigens such as mesothelin [199] and glypican-1 [200] in solid tumours including pancreatic cancer. Here, MSLN is linked to familial pancreatic carcinoma.